GHRP-2

GHRP-2 (Growth Hormone-Releasing Peptide-2), also known as pralmorelin or KP-102, is a synthetic hexapeptide that stimulates growth hormone secretion by activating the growth hormone secretagogue receptor (GHS-R1a). This receptor is naturally activated by ghrelin, a hormone involved in appetite regulation, energy balance, and growth hormone release. GHRP-2 acts on the hypothalamus and anterior pituitary to produce rapid increases in endogenous growth hormone, which may subsequently influence circulating insulin-like growth factor-1 (IGF-1). Its effects on GH secretion have been demonstrated repeatedly in controlled human studies.

Pralmorelin hydrochloride is approved in Japan as a diagnostic agent for assessing growth hormone deficiency, making GHRP-2 one of the relatively few research peptides with an established medical application in another country. Beyond diagnostic testing, investigators have examined its effects on appetite, cortisol, prolactin, age-related changes in GH secretion, and interactions with growth hormone-releasing hormone (GHRH). However, increased GH or IGF-1 does not automatically establish improved muscle growth, fat loss, exercise recovery, or longevity. Although GHRP-2 is frequently discussed in experimental bodybuilding and anti-aging communities, no controlled human trials establish the effectiveness or long-term safety of routine self-administered treatment for these purposes. GHRP-2 is not FDA-approved in the United States.

GHRP-2 stimulates growth hormone secretion through the ghrelin receptor system. Its strongest demonstrated effects involve rapid activation of the hypothalamic-pituitary growth hormone axis, with additional activity involving appetite and other endocrine pathways.

1. Ghrelin Receptor Activation

• GHRP-2 binds to and activates the growth hormone secretagogue receptor, GHS-R1a.
• This receptor is expressed in the hypothalamus, pituitary gland, and other tissues.
• Ghrelin normally activates GHS-R1a and participates in appetite and growth hormone regulation.
• GHRP-2 acts as a synthetic ghrelin receptor agonist, producing strong GH-releasing effects.
• Its activity is not identical to every physiological action of endogenous ghrelin.

2. Stimulation of Growth Hormone Pulses

• The anterior pituitary releases growth hormone in pulses throughout the day and night.
• GHRP-2 stimulates the GH secretory pathway through GHS-R1a activation and interactions with hypothalamic regulation.
• Controlled human experiments demonstrate rapid, dose-dependent increases in circulating GH.
• After intravenous administration in diagnostic research, GH commonly reaches its peak within approximately 60 minutes.
• The magnitude of the response depends on pituitary reserve, age, body composition, and other physiological factors.

3. Interaction With Growth Hormone-Releasing Hormone (GHRH)

• GHRH is a naturally occurring hypothalamic hormone that activates a different receptor from GHS-R1a.
• GHRP-2 and GHRH can stimulate GH secretion through complementary pathways.
• Some clinical experiments demonstrate an amplified or synergistic GH response when both are administered together.
• However, other controlled studies found largely additive responses rather than statistically confirmed synergy.
• The interaction depends on dose, exposure duration, age, sex, and underlying pituitary physiology.

4. Downstream IGF-1 Signaling

• Growth hormone stimulates IGF-1 production, particularly in the liver.
• IGF-1 participates in normal tissue growth, cellular maintenance, and metabolic regulation.
• Human studies have demonstrated increased circulating IGF-1 during sustained GHRP-2 exposure.
• IGF-binding proteins, including IGFBP-3 and IGFBP-5, were also affected in experimental studies.
• Increased IGF-1 does not independently establish improved muscle strength, tissue repair, or longevity.

5. Appetite Stimulation

• Ghrelin signaling plays an important role in hunger and food intake.
• GHRP-2 activates this pathway and has demonstrated direct orexigenic, or appetite-stimulating, effects in humans.
• Controlled experiments found that GHRP-2 increased food consumption in both lean and obese participants.
• This response is important because increased appetite may counteract goals involving calorie reduction and weight management.

6. ACTH and Cortisol Signaling

• ACTH is a pituitary hormone that stimulates cortisol production by the adrenal glands.
• GHRP-2 can also increase ACTH and cortisol concentrations during acute exposure.
• These effects have been documented in controlled human endocrine studies.
• Therefore, GHRP-2 should not be described as a fully selective GH secretagogue.
• The long-term significance of repeated cortisol stimulation remains insufficiently characterized.

7. Prolactin Responses

• Prolactin is a pituitary hormone involved in reproductive and other physiological processes.
• Human experiments demonstrate that GHRP-2 can increase circulating prolactin.
• The response is generally smaller than its GH-stimulating activity, but can be meaningful in endocrine research.
• Effects may differ depending on dose, baseline hormone status, and individual physiology.

8. Glucose and Insulin Regulation

• Growth hormone participates in glucose and lipid metabolism and can oppose some actions of insulin.
• Changes in GH and ghrelin receptor activity may influence insulin sensitivity and glucose regulation.
• The FDA has identified reports of increased insulin requirements in patients receiving GHRP-2, although causality has not been established.
• These concerns make metabolic safety an important unanswered question during repeated exposure.

9. Pituitary GH Reserve Testing

• Growth hormone deficiency can result from abnormalities involving the hypothalamus or pituitary gland.
• GHRP-2 challenges the GH secretory system and allows clinicians to measure the hormone response.
• Patients with adequate GH secretory reserve generally produce a larger response than patients with severe deficiency.
• Japan has approved pralmorelin hydrochloride for this diagnostic purpose.
• The test evaluates hormone secretion; the diagnostic approval does not establish a therapeutic indication.

10. Receptor Adaptation and Exposure Duration

• Growth hormone responses to secretagogues depend on dose, frequency, and duration of exposure.
• Some experimental models demonstrate attenuation of the hormonal response with repeated stimulation.
• However, a 30-day human infusion study demonstrated continued elevation of pulsatile GH secretion throughout the observation period.
• These findings do not establish that a particular self-administered cycle prevents tolerance or maintains clinical effectiveness.

The Key Difference: GHRP-2 reliably stimulates endogenous growth hormone and influences appetite and other pituitary hormones. However, producing a measurable GH pulse is not equivalent to demonstrating improved body composition, muscle strength, cardiovascular function, or biological aging in humans.

Researchers are interested in GHRP-2 because it provides a potent and measurable way to investigate growth hormone secretion, ghrelin receptor function, and broader endocrine regulation.

• Growth Hormone Deficiency: Approved in Japan as a diagnostic challenge agent for evaluating GH secretory reserve.
• GH Pulsatility: Controlled human studies demonstrate rapid, dose-dependent GH release.
• IGF-1 Regulation: Sustained exposure can elevate circulating IGF-1 and selected binding proteins.
• GHRH Interactions: Studies explore the complementary and sometimes synergistic GH responses produced through separate receptors.
• Appetite Research: Human studies demonstrate increased food intake following GHRP-2 exposure.
• Age-Related Endocrine Changes: Researchers have examined how older adults respond to GH secretagogues.
• Muscle Metabolism: GH/IGF-1 signaling provides a biological rationale for studying lean tissue and protein metabolism.
• Body Composition: Investigators are interested in GH-related lipolysis and energy balance, although clinical benefits remain unproven.
• Metabolic Regulation: Ghrelin receptor signaling intersects with insulin, glucose, appetite, and energy homeostasis.
• Endocrine Safety: Cortisol, prolactin, and ACTH responses help clarify the broader effects of secretagogues.
• Drug Development: GHRP-2 helps researchers compare short-acting ghrelin receptor agonists with other GH-axis interventions.

Research Limitation: Strong evidence of GH secretion does not establish that chronic GHRP-2 improves muscle growth, fat loss, exercise recovery, sleep, or longevity. These outcomes require separate clinical trials.

GHRP-2 has substantial human evidence demonstrating growth hormone stimulation and appetite-related effects. However, the strongest clinical findings concern hormonal biomarkers and diagnostic testing, not long-term improvements in strength, muscle mass, body fat, or longevity.

Notable Human Research Findings

GH Stimulation — Established Human Finding: A 1997 study examined GHRP-2 and hexarelin in healthy younger and older adults. Intravenous GHRP-2 produced a strong GH response, with greater responses at 2 mcg/kg than at 1 mcg/kg. The same experiments documented additional endocrine effects involving prolactin, ACTH, and cortisol.

Sustained GH and IGF-1 — 2004 Research: A study involving healthy older adults evaluated continuous subcutaneous GHRP-2 exposure for 30 days. The GH response was more than three times the saline response on day 1 and remained approximately 1.8 times the saline response on days 14 and 30. IGF-1 and selected IGF-binding proteins also increased. This finding demonstrates sustained hormonal responsiveness, not proven muscle growth or anti-aging benefits.

Appetite — 2005 Human Study: Seven healthy, lean men received controlled subcutaneous GHRP-2 or saline infusions. During a subsequent buffet meal, participants consumed approximately 35.9% more energy following GHRP-2 administration. All seven increased their food intake compared with saline.

Appetite — 2006 Dose-Response Study: A separate study involving ten lean and nine obese participants evaluated low-dose and high-dose subcutaneous infusions. Compared with placebo, energy intake increased by approximately 10.2% at the lower dose and 33.5% at the higher dose. The appetite-stimulating response was preserved in participants with obesity.

GH Deficiency Diagnostics — 2007 Study: Researchers examined 77 healthy participants and 58 patients with confirmed GH deficiency. A single 100 mcg intravenous GHRP-2 challenge produced substantially different GH responses between the groups. The study supported using the peptide to assess GH secretory reserve, with diagnostic interpretation depending on the hormone assay and calibration.

Muscle Growth and Lean Mass: Elevated GH and IGF-1 provide a physiological rationale for studying muscle-related outcomes. However, no adequately controlled human trial establishes that daily GHRP-2 injections produce clinically meaningful increases in skeletal muscle mass, muscle strength, or athletic performance.

Fat Loss: Growth hormone influences lipid metabolism, including lipolysis. Nevertheless, evidence that GHRP-2 injections produce sustained fat loss in healthy or overweight adults is insufficient. Increased hunger and food intake may counteract potential changes in lipid mobilization.

Recovery and Tissue Repair: GH and IGF-1 participate in normal tissue maintenance, but no controlled human study establishes faster tendon healing, wound repair, exercise recovery, or injury rehabilitation from GHRP-2 treatment.

Sleep and Longevity: Although endogenous GH secretion is closely associated with sleep physiology, no controlled clinical trial demonstrates that GHRP-2 improves sleep quality, reverses aging, reduces frailty, or extends lifespan.

Cardiovascular Health: Ghrelin-related signaling has been investigated in cardiovascular research, but direct clinical benefits from GHRP-2 for heart disease, circulation, or vascular aging remain unproven.

Research Perspective: The principal demonstrated outcomes are acute and sustained endocrine changes, diagnostic GH stimulation, and increased appetite. These findings support scientific interest without establishing routine therapeutic benefits for bodybuilding, metabolic optimization, or longevity.

GHRP-2 has been administered to humans through intravenous injection and controlled subcutaneous infusion. Japan has an approved, standardized diagnostic regimen using pralmorelin hydrochloride. However, no FDA-approved dose or clinically validated long-term treatment protocol exists for muscle growth, fat loss, exercise recovery, or anti-aging.

Published Clinical Dosing and Community-Reported Amounts

Important Distinction Between Diagnostic and Community Dosing

• Approved Diagnostic Use: The Japanese medical regimen involves a single physician-supervised intravenous challenge, with hormone measurements used to assess GH reserve.
• Continuous Infusion Research: Several human studies used precisely controlled infusion pumps over hours or weeks.
• Community Bolus Injections: Short subcutaneous injections described in informal protocols produce a different exposure pattern from continuous infusion.
• Not Interchangeable: A subcutaneous bolus of 100 mcg is not pharmacokinetically equivalent to an IV diagnostic dose of 100 mcg or a continuous infusion of 1 mcg/kg/hour.

Research Concentration Mathematics

A commonly described research preparation uses a nominal 10 mg vial with a final solution volume of 3.0 mL. If the vial contains 10,000 mcg of authentic active peptide and the final volume is exactly 3.0 mL, the nominal concentration is 3,333 mcg/mL, or 33.3 mcg per 0.01 mL. This is an arithmetic example rather than a validated injectable formulation.

Calculation Limitations: U-100 syringe graduations represent volume, not peptide mass. The calculation assumes the stated peptide quantity is accurate, the final volume is exact, and the measured concentration is uniform. None of these assumptions establishes sterile preparation, pharmaceutical suitability, accurate delivery, or a clinically appropriate dose.

Administration Timing and Nutrition

• Fasting: The approved Japanese diagnostic test is performed under fasting conditions. This helps standardize clinical hormone testing.
• Meal Timing: Claims that GHRP-2 must be administered exactly 20–30 minutes before or after eating to achieve useful effects are not established as a validated human treatment rule.
• Carbohydrates and Fat: Nutrition and metabolic state can influence GH physiology, but no controlled long-term GHRP-2 treatment trial establishes an optimal macronutrient-related injection window.
• Evening Administration: Often promoted to align with natural GH rhythms, but no clinical outcome study establishes superior benefits from evening versus morning dosing.

Formulation and Storage

• Japanese Pharmaceutical Product: The approved diagnostic preparation is pralmorelin hydrochloride supplied as a defined pharmaceutical product with its own preparation and storage instructions.
• Research-Market Material: Vials may contain acetate, hydrochloride, or other salt forms and may differ in quality and peptide content.
• Reconstitution: No universal bacteriostatic-water preparation procedure has been validated for research-market GHRP-2.
• Storage: Conditions depend on the specific product. The Japanese diagnostic product is labeled for cold storage, protected from freezing and light as specified.
• Post-Mixing Stability: Japan's pharmaceutical labeling directs preparation shortly before administration. A universal 28-day storage period for community-mixed products has not been established.
• Quality Control: Identity, purity, aggregation, sterility, endotoxin content, pH, and peptide stability are relevant to injectable safety.

Important Regulatory Safety Finding: The FDA has placed GHRP-2 for injectable and nasal administration in category 2 of its 503B bulk-substances evaluation due to potential significant safety risks, including immunogenicity associated with aggregation and peptide-related impurities.

Research Perspective: The table distinguishes established diagnostic dosing, human experimental exposure, and informal community amounts. No validated daily self-injection schedule, 8–16-week treatment course, or maximum tolerated long-term dose exists for GHRP-2 in healthy adults.

No clinically validated growth, recovery, fat-loss, or anti-aging cycle exists for GHRP-2. Published human research has ranged from single diagnostic challenges to continuous subcutaneous infusion lasting 30 days. Informal peptide communities describe substantially different once-daily injection schedules.

• Japanese Diagnostic Application: One supervised administration for GH secretory testing.
• Acute Endocrine Studies: Single-dose experimental challenges with hormone measurements over approximately one to two hours.
• Human Appetite Experiments: Controlled subcutaneous infusions lasting approximately 270 minutes.
• 1990s Repeated-Exposure Research: Investigated endocrine responses during approximately 7–30 days of administration.
• 2004 Older-Adult Study: Evaluated continuous subcutaneous GHRP-2 infusion for 30 days.
• Community Introductory Period: One to two weeks at a lower informal amount are sometimes discussed.
• Community Treatment Courses: Eight to sixteen weeks of daily administration are frequently promoted.
• Community Washout Periods: Several weeks between treatment courses are sometimes described without clinical validation.
• Extended Administration: Long-term safety and clinically meaningful outcomes from repeated daily injections remain unknown.

Important Tolerance Finding: A 1996 human study demonstrated that desensitization depended partly on dose and administration frequency. This suggests complex endocrine adaptation rather than a universal tolerance threshold.

Important 2004 Finding: The 30-day continuous infusion study found that pulsatile GH secretion remained elevated throughout treatment. The response was smaller on days 14 and 30 than on day 1, but persisted above control levels.

Once-Daily Claims: No human research establishes that administering GHRP-2 once daily prevents tachyphylaxis, maintains receptor sensitivity, or provides superior body-composition outcomes.

Washout Claims: No clinically validated interval has been established for restoring ghrelin receptor responsiveness or preventing endocrine adverse effects.

Research Perspective: The dose, delivery method, and duration influence endocrine responses. Published infusion experiments should not be converted into unsupported daily injection cycles for healthy adults.

GHRP-2 is frequently discussed in combination with other growth hormone secretagogues, GHRH analogues, and experimental anabolic compounds. The most directly supported biological interaction involves GHRP-2 and GHRH, which act through different receptors to influence GH secretion.

GHRH Combination Research: A 1995 study involving eight healthy men demonstrated that combining GHRP-2 with GHRH increased overall GH exposure compared with either compound alone, but the investigators did not establish statistically significant synergy beyond the sum of the individual responses.

Additional GHRH Findings: A later study involving healthy older adults found that certain GHRP-2/GHRH infusion combinations produced stronger GH responses than either secretagogue alone. This illustrates the importance of dosing conditions, age, and sex.

Important Receptor Distinction: Combining GHRP-2 with another ghrelin receptor agonist is different from combining it with a GHRH-receptor agonist. Similar receptor targets may produce overlapping effects rather than complementary signaling.

Safety Consideration: Additional GH-axis stimulation may increase uncertainty regarding IGF-1 exposure, glucose tolerance, fluid balance, cortisol, prolactin, and other hormone-related effects.

Research Perspective: Human endocrine studies support the biological interaction between GHRP-2 and GHRH. However, no controlled research establishes that these combinations improve muscle growth, fat loss, anti-aging outcomes, or long-term safety in healthy adults.

GHRP-2 has a more substantial human endocrine safety database than many investigational peptides because of its use in diagnostic testing and controlled research. However, tolerability following a single clinical challenge cannot establish the safety of repeated administration over weeks or months.

Reported Side Effects and Safety Considerations

Japanese Diagnostic Safety Data: The approved pralmorelin product information identifies sensations of warmth in approximately 16% of recipients. Abdominal rumbling and increased white blood cell counts were also reported in at least 5%. Other reported effects include hypotension, nausea, sweating, hunger, dizziness, and fatigue.

Cortisol and Prolactin: A controlled human endocrine study demonstrated that GHRP-2 stimulates prolactin, ACTH, and cortisol in addition to GH. Its effects are therefore broader than those of a completely GH-selective secretagogue.

Glucose and Insulin: Sustained GH stimulation may influence glucose regulation. The FDA has identified reports of increased insulin requirements in people receiving GHRP-2, although those reports do not prove that GHRP-2 caused the changes.

FDA Safety Warning: GHRP-2 for injectable and nasal use appears on the FDA's category 2 list of bulk substances presenting potential significant safety risks. The agency cites immunogenicity concerns arising from peptide aggregation, impurities, and structural characterization challenges.

Additional Serious Event Reports: The FDA reports awareness of infection, pancreatitis, and deaths involving critically ill recipients exposed to GHRP-2. These reports are important safety signals, but causality has not been established and they should not be presented as confirmed direct adverse effects.

Long-Term GH-Related Concerns: Persistently elevated GH or IGF-1 can influence fluid balance, glucose metabolism, and tissue growth. These physiological concerns are relevant to chronic secretagogue exposure but should not be confused with measured incidence rates from controlled long-term GHRP-2 trials.

Research Perspective: A single Japanese diagnostic challenge has an established medical safety framework. Repeated self-administered injections for body composition or anti-aging have not undergone equivalent clinical evaluation.

GHRP-2 has approved diagnostic product instructions in Japan, but no FDA-approved contraindication profile for chronic therapeutic use. Its effects on growth hormone, IGF-1, cortisol, prolactin, appetite, and glucose metabolism require consideration when evaluating experimental applications.

• Pregnancy: Pregnancy or suspected pregnancy is listed as a contraindication in Japanese pralmorelin product information.
• Breastfeeding: Japanese labeling advises consideration of diagnostic necessity and breastfeeding benefits; animal experiments indicate possible transfer into milk.
• Children Under Four: Japan's diagnostic product lacks adequate clinical safety and effectiveness data in this age group.
• Active Cancer: GH and IGF-1 participate in cellular growth pathways. The effects of repeated GHRP-2 exposure during malignancy are unknown.
• History of Cancer: Long-term effects on tumor-related outcomes have not been established.
• Pituitary Tumors: Pituitary disease requires specialist evaluation. Japanese labeling notes reports of pituitary apoplexy with related diagnostic agents in patients with pituitary adenomas.
• Diabetes: GH-related effects on glucose metabolism may complicate glycemic regulation. Insulin requirements and glucose responses warrant particular concern.
• Insulin Resistance / Prediabetes: Long-term metabolic outcomes from repeated GHRP-2 exposure remain uncertain.
• Obesity: GHRP-2 has demonstrated appetite stimulation in people with obesity, potentially complicating efforts to maintain a calorie deficit.
• Sleep Apnea: Sustained GH/IGF-1 changes have not been adequately evaluated in people with obstructive or central sleep apnea.
• Cardiovascular Disease: Changes in blood pressure, fluid balance, and endocrine signaling require further research.
• Fluid Retention Disorders: GH-axis effects may influence fluid regulation, although direct long-term GHRP-2 safety is unestablished.
• Hyperprolactinemia: GHRP-2 can stimulate prolactin release during acute endocrine testing.
• Adrenal Disorders: ACTH and cortisol responses could complicate interpretation of endocrine measurements.
• Elevated IGF-1: Additional stimulation of the GH axis may be inappropriate without medical evaluation of the underlying cause.
• Concurrent GH / GHRH Therapy: Overlapping endocrine stimulation may create unpredictable GH and IGF-1 exposure.
• Competitive Athletics: GHRP-2 is prohibited under WADA Section S2.2.4.
• Unregulated Injectable Products: Incorrect chemical forms, inaccurate quantities, impurities, and microbial contamination may pose significant risks.

Regulatory Status — Japan: Pralmorelin hydrochloride is approved for diagnostic assessment of growth hormone deficiency. The approval is for specialized clinical testing, not repeated treatment for muscle growth, fat loss, or anti-aging.

Regulatory Status — United States: GHRP-2 is not FDA-approved. The FDA has identified potential significant safety risks involving compounded injectable and nasal preparations.

Anti-Doping Status: The World Anti-Doping Agency prohibits GHRP-2 at all times as a growth hormone-releasing peptide.

Important Medical Distinction: GH deficiency should be diagnosed through appropriate clinical evaluation and validated stimulation testing. A single random GH measurement cannot reliably diagnose deficiency because GH secretion is naturally pulsatile.

Medical Consideration: Suspected GH deficiency, persistent fatigue, unexpected body-composition changes, or endocrine abnormalities require medical assessment rather than assuming that increasing growth hormone will produce beneficial outcomes.

GHRP-2 research primarily uses measurements of growth hormone secretion, downstream IGF-1 activity, other pituitary hormones, appetite, and metabolic responses. Clinical diagnostic testing and experimental long-term administration require different approaches to interpreting these measurements.

Japanese Diagnostic Testing: The standardized GH response to pralmorelin is evaluated using timed blood sampling following a single supervised administration. In research, samples have commonly been collected at baseline and at defined intervals such as 15, 30, and 45 minutes.

Diagnostic Cutoff Consideration: A 2007 validation study associated a peak GH threshold of approximately 15 mcg/L with severe GH deficiency using one assay system. With a later standardized calibration, the corresponding threshold was approximately 9 mcg/L. Thresholds must be interpreted according to the validated test and laboratory method.

IGF-1 Consideration: Circulating IGF-1 provides information about downstream GH-axis activity, but a higher value does not independently establish greater muscle growth, better recovery, or improved health.

Glucose Safety: Given the relationship between GH physiology and insulin sensitivity, metabolic measurements are an important research consideration during prolonged endocrine stimulation.

Cortisol and Prolactin: Acute hormonal increases may be transient. A single elevated measurement does not independently establish persistent endocrine dysfunction.

Functional Outcomes: Changes in muscle mass, strength, fat mass, and exercise capacity require direct measurement. GH and IGF-1 are not substitutes for demonstrated clinical benefits.

Important Limitation: No blood test, biomarker panel, or monitoring interval has been validated to establish the safety or effectiveness of routine GHRP-2 injections for bodybuilding, fat loss, anti-aging, or wellness.